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Until the mid-1980s, most economic analyses of healthcare technologies were based on
decision theory and used decision-analytic models. The goal was to synthesize all relevant
clinical and economic evidence for the purpose of assisting decision makers to efficiently
allocate society’s scarce resources. This was true of virtually all the early cost-effectiveness
evaluations sponsored and/or published by the U.S. Congressional Office of Technology
Assessment (OTA) (15), Centers of Disease Control and Prevention (CDC), the National
Cancer Institute, other elements of the U.S. Public Health Service, and of healthcare tech-
nology assessors in Europe and elsewhere around the world. Methodologists routinely es-
poused, or at minimum assumed, that these economic analyses were based on decision theory
(8;24;25). Since decision theory is rooted in—in fact, an informal application of—Bayesian
statistical theory, these analysts were conducting studies to assist healthcare decision mak-
ing by appealing to a Bayesian rather than a classical, or frequentist, inference approach.
But their efforts were not so labeled. Oddly, the statistical training of these decision analysts
was invariably classical, not Bayesian. Many were not—and still are not—conversant with
Bayesian statistical approaches.
Thus, it should not come as a surprise that, when the pharmaceutical industry be-
gan to generate empirical, experimentally-based economic data alongside the empirical,
experimentally-based efficacy data, these analysts appealed to the only statistical training
they knew: classical, frequentist statistics. But they immediately ran into difficulties. For
instance, the clinical trials that generated the empirical data were always powered for clin-
ical, not economic endpoints. Thus, using frequentist rules, statements of “no difference”
were commonplace even when economic differences were observed but did not reach sta-
tistical significance and when accompanied by clinical differences that were expected to
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lead to economic efficiencies. Perhaps more problematic was the fact that the vehicle that
generated the data, the clinical trial, was a highly constrained, if not inappropriate, vehicle
to demonstrate economic consequences directly. Often the protocol itself induced health-
care utilization, in effect distorting the very evidence the researcher was trying to gather
experimentally. Furthermore, these analyses are limited to the empirical data from the study
at hand, and conversely do not take into account the full complement of knowledge and
beliefs surrounding the problem being addressed. All in all, the resulting evaluations have
not been shown to be of a great deal of use to healthcare decision makers. But this may be
changing.
There is a gathering movement in Western countries to more formally incorporate
economic evaluation with clinical evidence-based decision making. Virtually all of these
efforts presume, encourage, and sometimes even require modeling to accompany systematic
reviews of clinical evidence (10). Such is true of the Canadian Coordinating Office of Tech-
nology Assessment (CCOHTA), the U.K. National Institute for Clinical Excellence (NICE),
the Australian Pharmacy Benefits Advisory Committee (PBAC), the U.S. Blue Cross/Blue
Shield Technology Evaluation Center (TEC), and U.S. managed care organizations that
are adopting pharmacoeconomic guidelines. All the above efforts to formally synthesize
knowledge for decision making are quintessentially Bayesian in nature. The question is the
degree to which a more formal application of Bayesian statistics can and will be used and
how.
The purpose of this special issue is to provide an overview of selected aspects of the
Bayesian approach that are most useful in healthcare technology assessment. Nine articles
are included in this issue to either present the theoretical framework of the Bayesian methods
(part I) or their empirical applications (part II), providing a foundation to understanding the
Bayesian approaches to technology assessment and decision making.
Applications of the Bayesian approach in healthcare technology assessment can be
as straightforward as calculating a posterior distribution from Bayes formula or as so-
phisticated as finding optimal stopping rules for clinical trials (4;7) or reporting a cost-
effectiveness acceptability curve (16). The introductory article by Dr. John Hornberger re-
views the fundamental concepts of Bayesian reasoning and illustrates the Bayesian concept
through a simplified example and a more complicated study estimating treatment effects on a
population.
The field of healthcare technology assessment employs a variety of statistical tools
to quantify clinical and economic evidence. Drs. Frank Harrell and Ya-Chen Tina Shih
summarize the above statistical methods and demonstrate the advantages of the Bayesian
approach in quantifying and reporting scientific evidence and in assisting decision making.
As illustrated in this paper, one of the most attractive features of the Bayesian approach lies
in its ability to report multiple endpoints such as cost-effectiveness ratios simultaneously.
Loss function is a useful tool to explicitly express the decision maker’s objective.
Optimal decision making is then achieved through either maximizing expected utility or
minimizing expected loss. The paper by Drs. Mohan Bala and Josephine Mauskopf in-
corporates the conjoint analysis technique in the estimation of the Bayesian loss function,
which is then used to guide decision making by choosing the “action” that minimizes the
“loss.” Through a simplified example, the authors introduce an innovative way to conduct
cost-benefit analyses using a Bayesian approach.
Another important Bayesian concept is value of information analysis. A Bayesian
decision theoretic approach utilizing the concept of “expected value of perfect information”
is presented by Dr. Karl Claxton and his co-authors. Through a policy model of Alzheimer’s
disease, the authors demonstrate how to use the Bayesian value of information analysis to
establish a technically efficient research design and to provide guidance to allocate research
and development resources optimally.
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In the concluding article for part I, Dr. Robert Winkler discusses the strength of the
Bayesian methods and weakness of the frequentist methods, explores the obstacles of using
the Bayesian approach in the current research environment from the philosophical and
practical aspects, and recommends strategies to increase the popularity of this approach.
Rather than seeking reconciliation, the author urges the Bayesian researchers to put extra
efforts in communicating with end-users at all levels and make this approach more user-
friendly.
A recent development in the methodologies of economic evaluation is the introduction
of the net health benefits approach (21) and the concept of cost-effectiveness acceptability
curve (23). In the empirical article by Dr. Andrew Briggs, an example of blood pressure
control among hypertensive type II diabetic patients is used to discuss the common ground
between Bayesian and frequentist approaches to stochastic cost-effectiveness analysis, to
demonstrate the Bayesian applications to the net health benefits approach, and to explore the
use and advantage of the cost-effectiveness acceptability curve. This article is an excellent
source for readers who are interested in learning both the classical and Bayesian applications
and interpretations of stochastic cost-effectiveness analysis.
Growing interests in the Bayesian approach among health researchers emerged upon
the publication of a Bayesian article by Brophy and Joseph (3). A Bayesian interpretation
challenging previous findings using the classical approach was presented in that paper,
after reanalyzing data in the Global Utilization of Streptokinase and t-PA for Occluded
Coronary Arteries (GUSTO) trial. Following the same effort, Dr. Dennis Fryback and his
co-authors conducted a Bayesian cost-effectiveness analysis reexamining the GUSTO car-
diovascular trial. This empirical paper provides a superb pedagogic example; it gives a
comprehensive demonstration of the Bayesian cost-effectiveness analysis, from the forma-
tion and parameterization of treatment alternatives to the computation and interpretation of
cost-effectiveness analysis results.
Several authors have pointed out that the advance in computing capability has greatly
eased the analytical burden experienced earlier by researchers using or wishing to use the
Bayesian techniques. The development of the Bayesian Inference Using Gibbs Sampling
(BUGS) program, which is a Bayesian statistical software based on the Markov Chain Monte
Carlo simulation technique, has made the Bayesian approach a lot more user-friendly for
researchers interested in applying this approach. In their software tutorial, Dr. Fryback and
his co-authors provide two teaching examples to demonstrate step by step how to structure
and analyze health economic studies using WinBUGS (Windows-based Bayesian Inference
Using Gibbs Sample). Readers who are interested in the Bayesian approach and want to
familiarize themselves with the BUGS software will benefit greatly from this introductory
tutorial.
As a final remark to this special issue, Dr. Steven Sheingold shares his thoughts on
Bayesian methods from a Medicare perspective and provides strategic advice for Bayesian
researchers to overcome the resistance toward this approach among policy and/or de-
cision makers. An analogy between the current development of the Bayesian approach
and the development of cost-effectiveness analysis in the past was drawn in his conclud-
ing remarks, suggesting that with proper communications and educational promotions,
greater understanding and acceptance of the Bayesian approach can be expected in the
future.
As demonstrated by articles included in this special issue, there are clear advantages
of taking a Bayesian view of probability to make useful inferences about both the effec-
tiveness and cost-effectiveness of healthcare technologies when decisions about adoption
must be made. However, Bayesian analysis can provide a much more comprehensive and
explicit framework when combined with decision theory. The possibilities of taking this
next logical step from Bayesian inference to a formal Bayesian decision theoretic approach
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to health technology assessment has been debated for some time (2;11). In point of fact,
until very recently the Bayesian decision theoretic approach has often been rejected within
the Bayesian biostatistics literature both on the grounds that specification of utilities is
rather speculative and due to the difficulty of combining resource use with a range of health
outcomes (1;19). However, even those that have rejected Bayesian decision theory in the
past accept that, at least in principle, this approach is more coherent than using inferential
rules where adoption decisions are based on conventional benchmark error probabilities
(levels of significance) such as 5% or 2.5%.
Recently there have been a number of developments in both the health economics
(4;5) and the biostatistics literature (7;9;22) that suggest that Bayesian decision theory is
both practical and useful, and a body of applied work in this area is starting to develop.
This more recent attention to the possibilities of using formal Bayesian decision theory can
provide tools to address some important policy issues such as the appropriate regulation
of healthcare technologies, setting priorities in research and development, and establishing
the efficient design of clinical research.
For example, the recent debate about the implementation of section 114 (Health Care
Economic Information) of the FDA Modernization Act has highlighted the issue of balanc-
ing the benefits of a regulatory agency demanding more information to substantiate a claim
about the cost-effectiveness of a new technology and the costs of acquiring that information
both in terms of resources and delayed adoption of cost-effective technologies. The general
debate has been taken up in the biostatistics literature (18), and a number of examples of the
use of Bayesian analysis in FDA submissions and a general interest in Bayesian methods by
the FDA can be identified (20). Others have also suggested that Bayesian decision theory
and value of information analysis provides a framework where the benefits and costs of
acquiring information before a claim can be made can be valued explicitly (6). Bayesian
decision theory may also provide the tools to address the incentive problems that arise when
agencies attempt to balance the efficient flow of pharmacoeconomic information with the
potential adverse incentives to research and development (14).
Similar issues are now faced in the United Kingdom by the NICE. Clearly, issues such
as combining data from a variety of sources in an explicit, transparent way and providing
probability statements directly relevant to a decision to adopt a technology are central to the
task that NICE faces. Although the primary question facing NICE is whether a technology
should be adopted by the NHS (which itself benefits from a Bayesian view of probability and
rejection of inferential rules), it can also issue guidance on the need for further investigation
and adoption conditional on further evidence (for example, recent guidance on primary hip
replacement) (12) or the results of pilot studies (for example, recent guidance on liquid-
based cytology) (13). Although the methodologic guidance adopted by NICE does not
promote a Bayesian inference or a Bayesian decision theoretical approach, NICE does
not necessarily discourage it. Indeed, the evaluation report for the appraisal of liquid-based
cytology presented an implicitly Bayesian value of information analysis based on a decision
theoretic model of cervical cancer screening (17).
Before the mid-1980s most economic evaluations were based on some form of decision
analytic modeling but without formal Bayesian statistical analysis. Until recently almost
all economic analyses of clinical trial data have been based on frequentist inference. The
general move toward evidence-based decision making provides an opportunity not simply
to substitute Bayesian inference for a frequentist analysis of clinical trial data but to adopt
formal Bayesian decision theory. Indeed, we believe that as the policy decisions and trade-
offs in health care are being posed more explicitly, approaches that offer both an explicit
and rigorous framework as well as that address directly the decisions themselves will likely
become more widely accepted.
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